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Synth=iis of the biolollically acti~ mctabolitc(s) from l¢-hydroxyvitamin D~ C lcKOH)D~) ~s  cxamiragl in various ty i~ of haman leukemia cell 
tin=, Untrcategl monocytoid leukemia e~lls (U937 and HELJS) metabolized Ia(OH)D~ Io the active metabolitc(s), Fouibly la.24- and/or Is. 
2S.dihydroxyvitamin D=. and th~a= cells were efficiently induced ¢o differentiate by treatment with Ia(OH}D~, However. the oth=r types of leukemia 
e.¢115 did not efficiently metabolize it and ~erc not induced to differentiate by I¢(OH)D~. The possible thcrapcutk: advantage of IcdOHlI~ in the 
tr~tment of monocyti¢ leukemia is discussed, 
Monocy|ic leukemia ~lh Vitamin D~ activation: DilTcr=ntiation 
I. INTRODUCTION 
The biologically active metabolit¢ of vitamin D~, 
lcz,25-dihydro~yvitamin D~ (I'r,25(OH)aD~), is a cal- 
cium-regulating hormone secreted by the kidney [1]. 
The hormone xerts its effect of inducing intestinal cal. 
cium transport and bone mineral mobilization activities 
by binding to a specific ytosol receptor in these organs. 
Some tumor ¢~lls also poss=,ss similar cyto~ol receptors 
to which la.25(OHhD~ binds specifically [2], 1¢.25 
(OH).,D;t inhibits cell growth and induces differentiation 
of some tumor ceils, including myelomonocytic leuke- 
mia cells [2,3]. 
Although I~{OH)D~ was only 0.01 as active 
I~¢,25(OH)aD~ in inducing differentiation a d inhibiting 
growth of mouse myeloid leukemia M l calls in vitro, 
Iu.(OH)D~ was more potent in enhancing the survival 
time of mice inoculated with the MI cells [4]. It has been 
reported that liver is a major site of 25.hydroxylation 
of vitamin D~, but tissu¢s other than the liver may also 
possess 25.hydroxylating ability [1], Activated macro- 
phages or I cz,25(OH)aD~.treat~d promyelocytic leuke- 
mia HL-60 cells have some vitamin D-metabolizing en- 
z'/mes, including the 24-hydroxylas¢ [5-7]. These results 
suggest that some myeloid leukemia c.¢lls may have the 
24- and/or 2~-hydroxylating activities, and that 
I~,(OH)D~, may be ¢fficiently metabolized toactive me- 
tabolite(s) in the leukemia c.¢lls. In the present experi- 
ment we examined the possibility of metabolic onver- 
sion of la(OH)D~ to the active metabolite(s) in the leu- 
kemia c~lls. 
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2. MATERIALS AND METHODS 
2. I . C r lh '  aud cell culture 
Human leukemia ¢=11 lin~ were cultural in luspcnsion in RPMI 
1640 medium supplemented with 10% fetal bovine ~rum at 37"C in 
u humidified atmosphere of S% CO: in air [8l, The human leukemia 
¢¢11 lines urcd in the premnt ¢xr~rimcnt war= as follows: U937 and 
HEL/S (monosytold}. K$62 and HEl.JO(crythmidL HL.6Oand ML-I 
(my¢loid). and BALL-i and MOLT4 (lymphoid}, 
2.2. A~a.t, uf ¢¢/l grmwh und praperfies of diff~reatiared cel/s 
Cell numbers were count~ in a Mod~l ZM Coulter Counter (Coal- 
tar EIc=lronics, Luton, UK), Nitro blue tetrazolium (NBT} reduction 
wa,= asrmycd as r¢~rtcd previously [9], i~OH)D~ aad i¢,25(OH)aD~ 
were obtained from Chuii=i Pharmaceutical Co, tTokyo}, 
2.3. flitu/ing assa~, of actire mctabalites 
The asray was pcrfonned by competition between unlal~lcd ,,-m- 
pl~ and ~H.lab~led 1¢,25(OH)=D~ forbinding a protein which has a 
hiBh specificity and affinity for I¢~,2S(OHhD ~, using an Ame~ham 
assay kit. 
3. RESULTS 
l~,25(OH),D~ dose-dependently induced NBT reduc- 
ing activity (a typical differentiation marker) of HL-60 
ceils and HEIJS ceils, and Icr.(OH)D= did not induce 
NBT reduction of HL.60 cells, as previously reported 
[2], however. HEIJ$ ¢¢11s were induced to differentiate 
by fez(OH)D=, and more cffficiently than IrL25(OH)=D= 
(Fig.l). To examine the metabolic activation of 
lcz(OH)D~ in leukemia cells° several typos of leukemia 
cells (5 x 10S/ml) were cultured with or without 100 
ng/ml of I~OH)D.~ for 24 h and the conditioned me- 
dium was harvested. Conversion of I~t(OH)D~ to an 
active metabolite was examined by inducin 8 NBT re. 
duction of HL-60 cells (Fig. 2). The conditioned me- 
dium from U937 or HEL/S cells significantly induced 
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Fig, I. Induction of NBT reduction ofHEL/S ceili by I¢(OH)D~. Cells 
were treated with variou~ concentratio~ of ltt(OH)D~ (o) or 
l=,25(OH);D~ (e) for 4 days. N~T reduction was ~prc~d as the '~ 
of NB'r-positlve cells. 
NBT reduction of HL.O0 ells, but not those t'rom the 
other cells. Although untreated HL-60 cells are promy- 
elocytic, monocytic differentiation of the HL-60 ~lls 
can be indued by several compounds. The HL.60 ~lls 
which were induced to monocytic differentiation by 
I~,25(OH)=D~ could metaboliz~ Iu.(OH)D= to an active 
metabolite(s), but the differentiated ceils by the other 
indu~rs could not metabolize the I=(OH)D~ (Table I). 
Conversion of I~(OH)D~ co an active metabolit¢, and 
metabolic inactivation of I¢,25(OH)=D~, increas~ with 
higher d=nsities of cultured ~lls and longer incubation 
times. In the culture of U937 c~lis (5 x 10=~lls/ml) with 
100 ng/ml of Ia(OH)D~, the NBT-inducing activity was 
not detected within 5 h, but thereafter increased to a 
maximal level at 2 days (Fig. 3). Metabolic inactivation 
of la,~-f(OH),D= was also observed in the U937 cells, 
but it was later than the activation of I-(OH)D~. The 
amount of 1 =,25(OH)=D~ in the conditioned medium of 
10t(OH)D~-trcated culture was determined by the radi- 
oree=ptor assay. A Breater than 100 molar excess of 
Io:,25(OI'I)a[~H]D, [2]. The result of" the radior=ccptor 
assay was consistent with that of induction of NBT 
rcduction (Fig. 3). 
Table 1 






of In(OH)D, (NBT 
reduction, A~dl0 ~ relier) 
None 1,3 + 0,6 |,1 + 0.8 
la,25(OH)=D~ ~i,9 ~ 1,4 2,? -+ !,2 
TNF¢ 5,2 ± 0,9 1,3 __. 0.6 
TPA ~,I .+0,7 i,1 +0,S 
Ketinoic ~cid 5.3 ~ 0.6 1,2 + 0,6 
HL.60 cells m<rc cultured with 100 riB/m! of Io.2$(OH)tD+, 2 ns/ml 
of tumor metro=i= factor a (TNFt¢), 0.5 n#ml of' 12-O-leer=de. 
¢anoylphorbol-13.aextatc (TPA), or 4 x i0 "~ M ~tinoi¢ acid for 4 
day=, NBT reducing activity in an aliquot of the tr~ted ¢ciltt wa= 
dettrmin¢d (Differtmiation). and the rcmaininM. ¢¢11,= wer¢ wa=htd 
with pho=phatc bulTcPed =aline, and th~n werecultared with 100 nllhnl 
of Io(OH)D~ for 2+ h. The r~ultin8 conditioned medium was col, 
letted and the metabolic activation of Io(OH)D~ wa,= ammytd by 
mcisurin8 NBT reduction ot" HL.60 cells alter treatment of the cell= 
with 10~i, (v/v) o1" the conditioned medium far 4 day~ (Metabolic 
activation of Ia(OH)D~). The conditioned medium from culture with. 
out ItKOH)D~ of the 1¢,2$~OHhD~-trcated cells watt armblc to induce 
NBT reduction of HL-60 cells, 
4. DISCUSSION 
Normal pulmonary macrophag~s arc known to 
metaboliz~ 25(OH)D~ by treatment ~l" the cells with 
interferan-?' or lipopolysaccharide [5,6]. The polar 
mctabolitcs were identified as hz,25(OH)aD~ and 
24,25(OH)~D~. It is of" interest to examine metabolism 
of vitamin D~ hz monocytic leukemia cells. Although 
some myelomonocyfic leukemia calls can metaboliz¢ 
25(OH)De, the metabolit¢ isolated is not a biologically 
active mctabolite such as I¢,25(OH)=D~ [7,10]. 
The present results clearly demonstrate hat the un- 
treated monocytic leukemia ~lls preferentially convert 
In(OH)D) to a biologically active m=tabolite(s). The 
metabolite(s) comigrated with authenti= I~,25(OH):D) 
on a Sephadex LH-20 chromatography column. The 
metabolit¢(s) had the same affinity for the 
l¢,25(OH):D~-specifi¢ receptor as authentic Ia,25 
(OH)aD~. However, we can not eliminate the possibility 
that the untreated monocytic leukemia cells can synthe- 
size I¢,24(OH)~D~ as well as I¢,25(OH)=D~. The 24- 
hydroxylas¢ was induced in interferon-z-stimulated 
macrophag~ and I=,25(OH)=D3-treatcd HL-60 cells, 
but not in the untreated ~lls [5,7]. Ia,24(OH)aD3 has a 
similar potency of inducing NBT reduction of HL-60 
cells and the same affinity for the specific receptor as 
Ic¢,25(OH)zD= [2]. 
Untreated monoeytic leukemia cells can metabolize 
induced to differentiate into mature macrophases b:~ 
their own metabolite(s). It is tempting to speculate on 
the th¢rapemic significance of the active metabolite(s). 
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FiG. 2, Activation of In(OH)D> in monocy|oid I=ukemia ¢¢11 lin~, 
Cells ($ x 10t/m[) were ¢uitur~;d witit (stippled bars) or without (open 
bars) 100 n=/ml of la (OH)D~ for 24 h, The condition=d medium was 
¢oll¢¢ted and added (final concentration, 10%) to the ¢uhur¢ of HL.60 
¢=lls for 4 days. Conversion of the active metabolite(s) w~s examined 
by induction of NBT reduc|ion, 
Our previous results indicate that I,~(OH)D= is more 
effective than Ice,25(OH)~D~ for enhancing the surviva! 
time of mice inoculated with mouse myeloid leukemia 
M 1 cells [4]. Endogenous cytokines, such as interferon- 
7. may induce 24- or 25-hydroxylas¢ activity in the 
inoculated M I cells and then the cells may convert 
I~.OH)D~ to l¢.25(OH)=D~ or l,~.24(OH).,D~. The m¢- 
tabolite(s) may be effective in inhibiting proliferation of 
their own c~lls and ia prolonging the survival time of the 
leukemic mice without any serious side effects. Because 
in viva administration of I~z(OH)D~ to mice resulted in 
no appreciable hypercalcemia [4], it might be useful for 
treatment of some types of ieukemias, including mon- 
ocyti¢ leukemia and vitamin D~.r=sponsive myeloid leu- 
kemia, 
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Fill. 3, Time-.courses of activation and inactivation of vitamin Dt in 
U937 c~lls, U937 c~lls (3 x 10~/ml) were treated with 100 ngml of 
Io(OH)D~ (It) or 1=,2S(OHL, D~ (o) for the indicated titan. The rmult. 
inll conditioned medium (final concentration 10~) wa= added to HLe 
60 cells. NST reduction of HL-60 ¢¢11s was examined ancr 4-d~y 
culture. II. amounts of la,25(OH)~D~-comp~titiv¢ ¢ompou~ch. Bars 
are means Z S,D. for thr~ different exFcriment~. 
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